このエントリーをはてなブックマークに追加
ID 50409
JaLCDOI
フルテキストURL
著者
Shien, Tadahiko Department of Breast and Endocrine Surgery, Okayama University Hospital ORCID Kaken ID publons researchmap
Kinoshita, Takayuki Department of Surgical Oncology, National Cancer Center Hospital
Seki, Kunihiko Department of Pathology, National Cancer Center Hospital
Yoshida, Miwa Department of Surgical Oncology, National Cancer Center Hospital
Hojo, Takashi Department of Surgical Oncology, National Cancer Center Hospital
Shimizu, Chikako Department of Medical Oncology, National Cancer Center Hospital
Taira, Naruto Department of Breast and Endocrine Surgery, Okayama University Hospital Kaken ID publons
Doihara, Hiroyoshi Department of Breast and Endocrine Surgery, Okayama University Hospital Kaken ID researchmap
Akashi-Tanaka, Sadako Department of Surgical Oncology, National Cancer Center Hospital
Tsuda, Hitoshi Department of Pathology, National Cancer Center Hospital
Fujiwara, Yasuhiro Department of Medical Oncology, National Cancer Center Hospital
抄録
While clinical and pathologic responses are important prognostic parameters, biological markers from core needle biopsy (CNB) are needed to predict neoadjuvant chemotherapy (NAC) response, to individualize treatment, and to achieve maximal efficacy. We retrospectively evaluated the cases of 183 patients with primary breast cancer who underwent surgery after NAC (anthracycline and taxane) at the National Cancer Center Hospital (NCCH). We analyzed EGFR, HER2, and p53 expression and common clinicopathological features from the CNB and surgical specimens of these patients. These biological markers were compared between sensitive patients (pathological complete response;pCR) and insensitive patients (clinical no change;cNC and clinical progressinve disease;cPD). In a comparison between the 9 (5%) sensitive patients and 30 (16%) insensitive patients, overexpression of p53 but not overexpression of either HER2 or EGFR was associated with a good response to NAC. p53 (p=0.045) and histological grade 3 (p=0.011) were important and significant predictors of the response to NAC. The correspondence rates for histological type, histological grade 3, ER, PgR, HER2, p53, and EGFR in insensitive patients between CNB and surgical specimens were 70%, 73%, 67%, 70%, 80%, 93%, and 73%. The pathologic response was significantly associated with p53 expression and histological grade 3. The correspondence rate of p53 expression between CNB and surgical specimens was higher than that of other factors. We conclude that the level of p53 expression in the CNB was an effective and reliable predictor of treatment response to NAC.
キーワード
breast cancer
neoadjuvant chemotherapy
predictors
Amo Type
Original Article
出版物タイトル
Acta Medica Okayama
発行日
2013-06
67巻
3号
出版者
Okayama University Medical School
開始ページ
165
終了ページ
170
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
英語
著作権者
CopyrightⒸ 2013 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT